Polyneuropathy

The FDA has granted regulatory approval for Wainua for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, according to a press release.

The FDA has approved Amvuttra, an RNA interference therapeutic for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Adults with type 2 diabetes are more likely to report falls and fear of falling than those without diabetes, regardless of the presence of diabetic polyneuropathy, according to a study published in Diabetic Medicine.

Among adults with type 2 diabetes, those reporting polyneuropathy pain have a significantly higher rate of major vascular events and are 42% more likely to die of any cause than those without pain.